Table 2.
Outcomes of study patients after EECP treatment
| Characteristics |
Median (IQR) |
||
|---|---|---|---|
|
Baseline |
End of 35th session |
Follow-up |
|
| (n = 30) | (n = 27) | (n = 30) | |
| Systolic blood pressure (mm Hg) |
122 |
120 |
130 |
| |
(113–133) |
(110–130) |
(120–130) |
|
p-value |
|
0.139a |
0.473b |
| Diastolic blood pressure (mm Hg) |
75 |
70 |
78 |
| |
(70–77) |
(70–80) |
(70–80) |
|
p-value |
|
0.839a |
0.431b |
| Heart rate (beats/min) |
70 |
68 |
71 |
| |
(61–75) |
(59–80) |
(63–80) |
|
p-value |
|
0.628a |
0.071b |
| Creatinine (mg/dL) |
1.02 |
0.97 |
1.01 |
| |
(0.84-1.36) |
(0.8-1.34) |
(0.85-1.36) |
|
p-value |
|
0.115a |
0.156b |
| GFR (mL/min per 1.73 m2) |
70.47 |
83.46 |
76.27 |
| |
(43.88-89.41) |
(47.26-97.51) |
(49.02-91.46) |
|
p-value |
|
0.075a |
0.006b** |
| Cystatin C (mg/L) |
1.00 |
0.91 |
0.94 |
| |
(0.78-1.31) |
(0.77-1.39) |
(0.77-1.27) |
|
p-value |
|
0.421a |
<0.001b** |
| NT-proBNP (pg/mL) |
244 |
200 |
210 |
| |
(120–1067) |
(70–653) |
(123–398) |
| p-value | 0.416a | 0.425b | |
aEnd of 35th session versus baseline, calculated using Wilcoxon signed ranks test.
bFollow-up versus baseline, calculated using Wilcoxon signed ranks test.
(**)indicated statistically significant p-value less than 0.01.